Navigation Links
FDA Approves Kalydeco to Treat Rare Form of Cystic Fibrosis
Date:1/31/2012

lydeco was approved ahead of the drug's April 18, 2012, prescription user fee goal date and is designated as an orphan drug, which identifies the disease as affecting fewer than 200,000 people in the United States.

In patients with the G551D mutation, Kalydeco, a pill taken two times a day with fat-containing food, helps the protein made by the CFTR gene function better and as a result, improves lung function and other aspects of CF such as increasing weight gain.

"Kalydeco is the first available treatment that targets the defective CFTR protein, which is the underlying cause of cystic fibrosis," said Janet Woodcock, M.D., director of the FDA's Center for Drug Evaluation and Research. "This is a breakthrough therapy for the cystic fibrosis community because current therapies only treat the symptoms of this genetic disease."

Two 48-week, placebo-controlled clinical studies involving 213 patients, one in patients ages 12 years and older and another in patients ages 6 years to 11 years, were used to evaluate the safety and efficacy of Kalydeco in CF patients with the G551D mutation. In both studies, treatment with Kalydeco resulted in significant and sustained improvement in lung function.

Kalydeco is effective only in patients with CF who have the G551D mutation. It is not effective in CF patients with two copies of the F508 mutation in the CFTR gene, which is the most common mutation that results in CF. If a patient's mutation status is not known, an FDA-cleared CF mutation test should be used to determine whether the G551D mutation is present.

The most common side effects of Kalydeco include upper respiratory tract infection, headache, stomach ache, rash, diarrhea, and dizziness.

Kalydeco is manufactured by Vertex Pharmaceuticals Inc. of Cambridge, Mass.

For more information:

FDA Voice Blog: How science and collaboration led to a new, "personalized" cystic fibrosis treatment for some patients

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Critical Care, a LifeCentre partner practice, located at 165 Fort Evans ... in Loudoun County to receive a small ... Barnes , Medical Director, is a well-seasoned veterinarian of more than ... are avid scuba divers. "As altitude skiers and hikers, we recognize ...
(Date:1/14/2014)... 14, 2014 NineSigma , Inc., the leading ... Innovation Leadership Summit , May 14-16, 2014 at the ... Ohio . This is the ... to breakthrough achievements through open innovation. Participants will learn ...
(Date:1/14/2014)... , January 14, 2014 ... Transfer Devices (CSTD) for hazardous drugs, today announced that it ... fourth straight year.   Equashield,s closed ... technicians, pharmacists, nurses and other medical professionals who ...
Breaking Medicine Technology:Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2
... 14, 2011 Berger Health System, recognized as one ... Association, upgrades to AutoCarousel® HD by Talyst, a leader ... control, and has a built-to-last 10 years guarantee. ... five years, is also implementing AutoPharm®, AutoPack™ and AutoLabel® ...
... Dec. 14, 2011 Lineagen, Inc., an innovative molecular ... Fast Forward, LLC, a nonprofit subsidiary of the National ... the clinical development and validation of a blood-based assay ... is to develop a test that can aid clinicians ...
Cached Medicine Technology:Berger Health System Partners With Pharmacy Automation Leader to Improve Patient Safety 2Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 2Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 3Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 4
(Date:4/23/2014)... Effects of Midlife Occupational and Leisure Time Physical Activity ... physical activity in midlife increases the risk of mobility ... the risk. This is found in a study which ... The study was conducted at the Gerontology Research Center ... , Heavy physical labor is often repetitive, wears the ...
(Date:4/23/2014)... that proliferation of endogenous neural precursor cells cannot ... axons. From the perspective of neural plasticity, Dr. ... in China observed the effects of functional electrical ... and expression of basic fibroblast growth factor and ... the infarct side. The researchers found that functional ...
(Date:4/22/2014)... leaders visited the New Jersey Institute of Technology ... Bloom for the launch of the New Jersey ... a new model for business innovation through the ... and investment. U.S. Senator Cory Booker, Panasonic Corp. ... New Jersey Lieutenant Governor Kim Guadagno, New Jersey ...
(Date:4/22/2014)... provide primary care for low-income patients may ease ... companies while improving patient health, researchers have concluded. ... health clinics that avoid costs associated with insurance ... hospital admission rates and emergency room visits, according ... Altoona. , The researchers estimated that the ...
(Date:4/22/2014)... women using a newer method of planned sterilization called ... a 10-year period than using the more commonly performed ... and UC Davis has found. , Published online ... study found the higher risk of pregnancy with a ... , "This study provides essential information for women ...
Breaking Medicine News(10 mins):Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3
... findings on a novel combination treatment approach for a ... (embargoed for 4 pm) in JAMA,s Archives of ... at University Hospitals (UH) Case Medical Center and Case ... outlines findings from a first-of-its-kind study showing that O6-benzylguanine ...
... malaria in Africa could be dashed by the emergence of ... the Malaria Journal . Unless urgent action is taken ... could be put at risk. In a study published ... of medicines on sale in Africa that have been deliberately ...
... to tackle the different work factors that are important to ... attachment that many nurses feel to the profession. Those are ... nurses published in the January issue of the Journal ... from seven private hospitals in four states, breaking them down ...
... the Upchurch Endowed Professor of Computer Science and coordinator ... co-edited a new book on computational modeling methods that ... critical support and better care options for patients. ... eye disorders such as cataracts and glaucoma are collected ...
... NJ -- Wiley-Blackwell, the scientific, technical, medical and scholarly ... announced the launch of Cancer Medicine , a ... is a peer reviewed, open access, interdisciplinary journal providing ... and clinical researchers across all the oncologic specialties in ...
... Reporter , MONDAY, Jan. 16 (HealthDay News) -- Gastric ... than does gastric banding, according to a new study ... Roux-en-Y involves reducing stomach size with staples and connecting ... is irreversible. Gastric banding, as its name implies, ...
Cached Medicine News:Health News:UH Case Medical Center publishes study on novel treatment for skin lymphoma 2Health News:Counterfeit and substandard anti-malaria drugs threaten crisis in Africa, experts warn 2Health News:Counterfeit and substandard anti-malaria drugs threaten crisis in Africa, experts warn 3Health News:Retention study identifies key factors affecting 3 generations of nurses 2Health News:Retention study identifies key factors affecting 3 generations of nurses 3Health News:Louisiana Tech professor co-edits book on computational analysis of human eye 2Health News:Major cancer societies to support new Wiley Open Access Journal 2Health News:More, Faster Weight Loss Seen With Gastric Bypass Than Banding 2Health News:More, Faster Weight Loss Seen With Gastric Bypass Than Banding 3Health News:More, Faster Weight Loss Seen With Gastric Bypass Than Banding 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: